Nivolumab (Nivo) Plus Chemotherapy (Chemo) Or Ipilimumab (Ipi) Vs Chemo As First-Line (1l) Treatment For Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma (Gc/Gejc/Eac): Checkmate 649 Study

CheckMate 649, a randomized, global phase 3 study of 1L programmed death (PD) 1 inhibitor-based therapies in advanced GC/GEJC/EAC, demonstrated superior overall survival (OS) with NIVO + chemo vs chemo, leading to US FDA approval. We report longer-term follow-up for NIVO + chemo vs chemo and first results for NIVO + IPI vs chemo.